Do analysts rate NEOV or NMAD?

NeoVolta presently has a consensus target price of $9.50, indicating a potential upside of 219.87%. Given NeoVolta's stronger consensus rating and higher probable upside, analysts plainly believe NeoVolta is more favorable than Lixte Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NeoVolta 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Lixte Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer NEOV or NMAD?

In the previous week, NeoVolta had 2 more articles in the media than Lixte Biotechnology. MarketBeat recorded 4 mentions for NeoVolta and 2 mentions for Lixte Biotechnology. Lixte Biotechnology's average media sentiment score of 0.73 beat NeoVolta's score of 0.72 indicating that Lixte Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeoVolta 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lixte Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate NMAD or SKYX?

SKYX Platforms has a consensus target price of $4.50, indicating a potential upside of 547.48%. Given SKYX Platforms' stronger consensus rating and higher probable upside, analysts clearly believe SKYX Platforms is more favorable than Lixte Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lixte Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SKYX Platforms 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75

Does the media refer more to NMAD or SKYX?

In the previous week, SKYX Platforms had 10 more articles in the media than Lixte Biotechnology. MarketBeat recorded 12 mentions for SKYX Platforms and 2 mentions for Lixte Biotechnology. Lixte Biotechnology's average media sentiment score of 0.73 beat SKYX Platforms' score of 0.52 indicating that Lixte Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lixte Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SKYX Platforms 2 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate NMAD or CBAT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lixte Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 China BAK Battery 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to NMAD or CBAT?

In the previous week, Lixte Biotechnology and Lixte Biotechnology both had 2 articles in the media. China BAK Battery's average media sentiment score of 0.91 beat Lixte Biotechnology's score of 0.73 indicating that China BAK Battery is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lixte Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive China BAK Battery 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer NMAD or BLNK?

Blink Charging has a consensus price target of $2.50, suggesting a potential upside of 423.45%. Given Blink Charging's stronger consensus rating and higher probable upside, analysts clearly believe Blink Charging is more favorable than Lixte Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lixte Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Blink Charging 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor NMAD or BLNK?

In the previous week, Blink Charging had 10 more articles in the media than Lixte Biotechnology. MarketBeat recorded 12 mentions for Blink Charging and 2 mentions for Lixte Biotechnology. Lixte Biotechnology's average media sentiment score of 0.73 beat Blink Charging's score of 0.39 indicating that Lixte Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lixte Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Blink Charging 2 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Lixte Biotechnology (NMAD) Competitors

$3.75 -0.03 (-0.79%)

As of 04:00 PM Eastern

Compare

NMAD vs. ABAT, NEOV, SKYX, CBAT, and BLNK

Should you buy Lixte Biotechnology stock or one of its competitors? Lixte Biotechnology's main competitors and comparable companies include American Battery Technology (ABAT), NeoVolta (NEOV), SKYX Platforms (SKYX), China BAK Battery (CBAT), and Blink Charging (BLNK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "electrical components & equipment" industry.

How does Lixte Biotechnology compare to American Battery Technology?

American Battery Technology (NASDAQ:ABAT) and Lixte Biotechnology (NASDAQ:NMAD) are both small-cap industrials companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, media sentiment, institutional ownership and valuation.

American Battery Technology has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market. Comparatively, Lixte Biotechnology has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market.

Lixte Biotechnology has lower revenue, but higher earnings than American Battery Technology. Lixte Biotechnology is trading at a lower price-to-earnings ratio than American Battery Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
American Battery Technology	$21.74M	8.66	-$73.38M	-$0.57	N/A
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.00	N/A

In the previous week, Lixte Biotechnology had 1 more articles in the media than American Battery Technology. MarketBeat recorded 2 mentions for Lixte Biotechnology and 1 mentions for American Battery Technology. American Battery Technology's average media sentiment score of 1.82 beat Lixte Biotechnology's score of 0.73 indicating that American Battery Technology is being referred to more favorably in the media.

Company	Overall Sentiment
American Battery Technology	Very Positive
Lixte Biotechnology	Positive

Lixte Biotechnology has a net margin of 0.00% compared to American Battery Technology's net margin of -337.50%. American Battery Technology's return on equity of -64.63% beat Lixte Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
American Battery Technology	-337.50%	-64.63%	-61.52%
Lixte Biotechnology	N/A	-75.49%	-62.03%

9.9% of American Battery Technology shares are held by institutional investors. Comparatively, 5.1% of Lixte Biotechnology shares are held by institutional investors. 7.8% of American Battery Technology shares are held by company insiders. Comparatively, 7.3% of Lixte Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

American Battery Technology currently has a consensus target price of $6.00, indicating a potential upside of 354.55%. Given American Battery Technology's stronger consensus rating and higher possible upside, equities research analysts plainly believe American Battery Technology is more favorable than Lixte Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
American Battery Technology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

American Battery Technology beats Lixte Biotechnology on 12 of the 16 factors compared between the two stocks.

How does Lixte Biotechnology compare to NeoVolta?

NeoVolta (NASDAQ:NEOV) and Lixte Biotechnology (NASDAQ:NMAD) are both small-cap industrials companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership.

NeoVolta presently has a consensus target price of $9.50, indicating a potential upside of 219.87%. Given NeoVolta's stronger consensus rating and higher probable upside, analysts plainly believe NeoVolta is more favorable than Lixte Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeoVolta	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NeoVolta has a beta of -0.71, suggesting that its share price is 171% less volatile than the broader market. Comparatively, Lixte Biotechnology has a beta of 1.37, suggesting that its share price is 37% more volatile than the broader market.

In the previous week, NeoVolta had 2 more articles in the media than Lixte Biotechnology. MarketBeat recorded 4 mentions for NeoVolta and 2 mentions for Lixte Biotechnology. Lixte Biotechnology's average media sentiment score of 0.73 beat NeoVolta's score of 0.72 indicating that Lixte Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeoVolta	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lixte Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lixte Biotechnology has a net margin of 0.00% compared to NeoVolta's net margin of -161.10%. Lixte Biotechnology's return on equity of -75.49% beat NeoVolta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeoVolta	-161.10%	-124.51%	-87.64%
Lixte Biotechnology	N/A	-75.49%	-62.03%

5.1% of NeoVolta shares are held by institutional investors. Comparatively, 5.1% of Lixte Biotechnology shares are held by institutional investors. 4.0% of NeoVolta shares are held by company insiders. Comparatively, 7.3% of Lixte Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Lixte Biotechnology has lower revenue, but higher earnings than NeoVolta. NeoVolta is trading at a lower price-to-earnings ratio than Lixte Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeoVolta	$13.33M	13.17	-$21.47M	-$0.52	N/A
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.00	N/A

Summary

Lixte Biotechnology beats NeoVolta on 8 of the 15 factors compared between the two stocks.

How does Lixte Biotechnology compare to SKYX Platforms?

Lixte Biotechnology (NASDAQ:NMAD) and SKYX Platforms (NASDAQ:SKYX) are both small-cap industrials companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

5.1% of Lixte Biotechnology shares are owned by institutional investors. Comparatively, 11.8% of SKYX Platforms shares are owned by institutional investors. 7.3% of Lixte Biotechnology shares are owned by company insiders. Comparatively, 24.2% of SKYX Platforms shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Lixte Biotechnology has a beta of 1.37, indicating that its share price is 37% more volatile than the broader market. Comparatively, SKYX Platforms has a beta of -3623.05, indicating that its share price is 362,405% less volatile than the broader market.

In the previous week, SKYX Platforms had 10 more articles in the media than Lixte Biotechnology. MarketBeat recorded 12 mentions for SKYX Platforms and 2 mentions for Lixte Biotechnology. Lixte Biotechnology's average media sentiment score of 0.73 beat SKYX Platforms' score of 0.52 indicating that Lixte Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lixte Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SKYX Platforms	2 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Lixte Biotechnology has a net margin of 0.00% compared to SKYX Platforms' net margin of -34.34%. SKYX Platforms' return on equity of 0.00% beat Lixte Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lixte Biotechnology	N/A	-75.49%	-62.03%
SKYX Platforms	-34.34%	N/A	-49.28%

SKYX Platforms has a consensus target price of $4.50, indicating a potential upside of 547.48%. Given SKYX Platforms' stronger consensus rating and higher probable upside, analysts clearly believe SKYX Platforms is more favorable than Lixte Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
SKYX Platforms	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Lixte Biotechnology has higher earnings, but lower revenue than SKYX Platforms. Lixte Biotechnology is trading at a lower price-to-earnings ratio than SKYX Platforms, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.00	N/A
SKYX Platforms	$92.01M	1.04	-$33.42M	-$0.27	N/A

Summary

SKYX Platforms beats Lixte Biotechnology on 12 of the 16 factors compared between the two stocks.

How does Lixte Biotechnology compare to China BAK Battery?

Lixte Biotechnology (NASDAQ:NMAD) and China BAK Battery (NASDAQ:CBAT) are both small-cap industrials companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Lixte Biotechnology and Lixte Biotechnology both had 2 articles in the media. China BAK Battery's average media sentiment score of 0.91 beat Lixte Biotechnology's score of 0.73 indicating that China BAK Battery is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lixte Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
China BAK Battery	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lixte Biotechnology has a net margin of 0.00% compared to China BAK Battery's net margin of -7.43%. China BAK Battery's return on equity of -15.32% beat Lixte Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lixte Biotechnology	N/A	-75.49%	-62.03%
China BAK Battery	-7.43%	-15.32%	-4.23%

Lixte Biotechnology has higher earnings, but lower revenue than China BAK Battery. China BAK Battery is trading at a lower price-to-earnings ratio than Lixte Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.00	N/A
China BAK Battery	$229.87M	0.37	-$9.38M	-$0.18	N/A

Lixte Biotechnology has a beta of 1.37, indicating that its share price is 37% more volatile than the broader market. Comparatively, China BAK Battery has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
China BAK Battery	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

5.1% of Lixte Biotechnology shares are owned by institutional investors. Comparatively, 2.0% of China BAK Battery shares are owned by institutional investors. 7.3% of Lixte Biotechnology shares are owned by company insiders. Comparatively, 0.8% of China BAK Battery shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

China BAK Battery beats Lixte Biotechnology on 6 of the 11 factors compared between the two stocks.

How does Lixte Biotechnology compare to Blink Charging?

Lixte Biotechnology (NASDAQ:NMAD) and Blink Charging (NASDAQ:BLNK) are both small-cap industrials companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

5.1% of Lixte Biotechnology shares are owned by institutional investors. Comparatively, 44.6% of Blink Charging shares are owned by institutional investors. 7.3% of Lixte Biotechnology shares are owned by company insiders. Comparatively, 1.8% of Blink Charging shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Lixte Biotechnology has higher earnings, but lower revenue than Blink Charging. Lixte Biotechnology is trading at a lower price-to-earnings ratio than Blink Charging, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.00	N/A
Blink Charging	$103.52M	0.67	-$83.39M	-$0.45	N/A

In the previous week, Blink Charging had 10 more articles in the media than Lixte Biotechnology. MarketBeat recorded 12 mentions for Blink Charging and 2 mentions for Lixte Biotechnology. Lixte Biotechnology's average media sentiment score of 0.73 beat Blink Charging's score of 0.39 indicating that Lixte Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lixte Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Blink Charging	2 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Lixte Biotechnology has a net margin of 0.00% compared to Blink Charging's net margin of -64.89%. Blink Charging's return on equity of -56.22% beat Lixte Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lixte Biotechnology	N/A	-75.49%	-62.03%
Blink Charging	-64.89%	-56.22%	-23.19%

Blink Charging has a consensus price target of $2.50, suggesting a potential upside of 423.45%. Given Blink Charging's stronger consensus rating and higher probable upside, analysts clearly believe Blink Charging is more favorable than Lixte Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Blink Charging	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Lixte Biotechnology has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market. Comparatively, Blink Charging has a beta of 2.08, suggesting that its stock price is 108% more volatile than the broader market.

Summary

Blink Charging beats Lixte Biotechnology on 11 of the 15 factors compared between the two stocks.

Get Lixte Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NMAD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NMAD vs. The Competition

Export

Metric	Lixte Biotechnology	Electrical Equipment Industry	Industrials Sector	NASDAQ Exchange
Market Cap	$60.86M	$9.28B	$10.17B	$12.22B
Dividend Yield	N/A	2.39%	2.93%	4.44%
P/E Ratio	N/A	39.09	32.86	30.86
Price / Sales	N/A	4.34	3.25	5.81
Price / Cash	N/A	27.44	20.29	22.66
Price / Book	3.57	3.93	3.89	3.79
Net Income	-$6.01M	$149.01M	$609.27M	$390.16M
7 Day Performance	4.17%	-2.00%	-0.21%	-1.10%
1 Month Performance	-17.22%	-11.11%	-1.81%	-6.19%
1 Year Performance	-14.97%	-18.88%	2.52%	-5.75%

Lixte Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NMAD Lixte Biotechnology	0.2322 of 5 stars	$3.75 -0.8%	N/A	-12.5%	$60.86M	N/A	N/A	4
ABAT American Battery Technology	2.2826 of 5 stars	$1.33 +10.9%	$6.00 +352.8%	-69.2%	$188.92M	$21.74M	N/A	195	Gap Up
NEOV NeoVolta	3.5084 of 5 stars	$2.53 +19.7%	$9.50 +276.2%	-29.3%	$149.24M	$13.33M	N/A	41	Upcoming Earnings
SKYX SKYX Platforms	2.771 of 5 stars	$0.73 +6.8%	$4.50 +519.0%	-54.0%	$100.54M	$96.20M	N/A	73	News Coverage Upcoming Earnings Analyst Downgrade Gap Up
CBAT China BAK Battery	1.0911 of 5 stars	$1.05 +2.9%	N/A	+2.6%	$93.08M	$195.19M	N/A	1,739

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NMAD) was last updated on 11/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lixte Biotechnology (NMAD) Competitors

NMAD vs. ABAT, NEOV, SKYX, CBAT, and BLNK

How does Lixte Biotechnology compare to American Battery Technology?

Summary

How does Lixte Biotechnology compare to NeoVolta?

Summary

How does Lixte Biotechnology compare to SKYX Platforms?

Summary

How does Lixte Biotechnology compare to China BAK Battery?

Summary

How does Lixte Biotechnology compare to Blink Charging?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMAD vs. The Competition

Lixte Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lixte Biotechnology (NMAD) Competitors

NMAD vs. ABAT, NEOV, SKYX, CBAT, and BLNK

How does Lixte Biotechnology compare to American Battery Technology?

Which has more risk & volatility, ABAT or NMAD?

Which has stronger earnings and valuation, ABAT or NMAD?

Does the media prefer ABAT or NMAD?

Is ABAT or NMAD more profitable?

Do institutionals & insiders believe in ABAT or NMAD?

Do analysts rate ABAT or NMAD?

Summary

How does Lixte Biotechnology compare to NeoVolta?

Do analysts rate NEOV or NMAD?

Which has more volatility and risk, NEOV or NMAD?

Does the media prefer NEOV or NMAD?

Is NEOV or NMAD more profitable?

Do insiders and institutionals believe in NEOV or NMAD?

Which has preferable earnings & valuation, NEOV or NMAD?

Summary

How does Lixte Biotechnology compare to SKYX Platforms?

Do insiders & institutionals hold more shares of NMAD or SKYX?

Which has more volatility & risk, NMAD or SKYX?

Does the media refer more to NMAD or SKYX?

Is NMAD or SKYX more profitable?

Do analysts rate NMAD or SKYX?

Which has higher earnings & valuation, NMAD or SKYX?

Summary

How does Lixte Biotechnology compare to China BAK Battery?

Does the media refer more to NMAD or CBAT?

Is NMAD or CBAT more profitable?

Which has preferable earnings and valuation, NMAD or CBAT?

Which has more risk and volatility, NMAD or CBAT?

Do analysts rate NMAD or CBAT?

Do institutionals and insiders believe in NMAD or CBAT?

Summary

How does Lixte Biotechnology compare to Blink Charging?

Do insiders and institutionals have more ownership in NMAD or BLNK?

Which has preferable earnings and valuation, NMAD or BLNK?

Does the media favor NMAD or BLNK?

Is NMAD or BLNK more profitable?

Do analysts prefer NMAD or BLNK?

Which has more volatility & risk, NMAD or BLNK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMAD vs. The Competition

Lixte Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools